This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 Allergy and Infectious Diseases Research) provides $1,563,642 to The Regents of the University of California, San Francisco to conduct a randomized, directly observed therapy (DOT) study on doxycycline post-exposure prophylaxis (doxy-PEP) for bacterial sexually transmitted infections (STIs). The study aims to develop in-depth adherence measurement techniques for doxycycline and establish dosing...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $490,788 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF). The grant, titled "Quantifying Genomic and Pharmacometabolomic Differences in Antiretroviral Exposure in MACS/WIHS Combined Cohort Study", aims to identify genetic and metabolic factors that influence the plasma concentrations and associated...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,233,520 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University. The goal of this 5-year project, titled "CHIPP-PREP: Cabotegravir-Hormone Interrogation of Pharmacokinetics/Pharmacodynamics for HIV Prevention in Cisgender and Transgender Persons," is to characterize the relationship between gender-affirming hormone therapy and long-acting...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $911,400 Project Grant to Emory University to establish the PREMISE (PrEP Epidemiology, Modeling, and Surveillance) system. The goal is to use national PrEP prescription data, legal/policy coding, and natural experimental designs to inform the U.S. HIV epidemic response and understand which programs and policies are effective at facilitating...
This federal Project Grant award, with a total funding of $856,202, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant will support a study entitled "STUDY OF ACUTE HIV FOR INVESTIGATING ERADICATION STRATEGIES (STAGES): THE ROLE OF IL-10 AND IFN SIGNALING" conducted by the Regents of the University of California, San Francisco (UCSF). The goal of the research is to...
The City & County of San Francisco's Public Health Department was awarded a $480,000 cooperative agreement from the Centers for Disease Control and Prevention (CDC) under the Sexually Transmitted Diseases (STD) Prevention and Control Grants program (CFDA 93.977). The award will fund the San Francisco STI Surveillance Network (SSUN) project over a 5-year period from September 2024 to September 2029. The project aims to strengthen STD prevention and control efforts in San Francisco through...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $1,533,177 Cooperative Agreement under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco (UCSF) to conduct a Phase 1 randomized, placebo-controlled safety study of MUCOCEPT-CVN, a live biotherapeutic product containing genetically engineered Lactobacillus jensenii 1153-1666 that secretes an HIV entry inhibitor. The study aims to evaluate...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a 5-year, $395,496 Project Grant (CFDA 93.855 - Allergy and Infectious Diseases Research) to The Regents of the University of California, San Francisco (UCSF) effective August 23, 2024. The funding will support a research project titled "Metagenomic Surveillance of Pathogen and Antimicrobial Resistance Gene Transmission in Hospitalized Neonates." The project aims to leverage metagenomic next-generation sequencing...
This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $794,045 to the Regents of the University of California, San Francisco (UCSF) to study host mechanisms that drive HIV reservoir decay and sustained viral control. The goal is to identify potential therapeutic candidates for HIV cure strategies. The award funds research to characterize the role of class II...
This $1,542,980 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research to explore the impact of gender-affirming hormone therapy on HIV viral dynamics and immune responses in transgender women. The award supports two key research cohorts: 1) a cross-sectional cohort of 120 transgender women, evenly divided by HIV serostatus and hormone exposure, and 2) a cohort of...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $4,884,540 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Regents of the University of California, San Francisco. The grant will fund a 5-year longitudinal cohort study to evaluate the field effectiveness of doxycycline as post-exposure prophylaxis (doxy-PEP) for sexually transmitted infections (STIs) among men who have sex with men and transgender women in 5 U.S. cities. The study aims to assess doxy-PEP uptake, adherence, and persistence, as well as its impact on antimicrobial resistance in gonorrhea and other bacteria. The study will enroll approximately 2,500 participants and involves sub-awards to the University of Washington, City & County of San Francisco, Wayne State University, San Francisco AIDS Foundation, and Emory University to support site implementation, recruitment, data collection, and qualitative research.